Mesoblast Limited (AU:MSB)
ASX:MSB
MSB Stock Chart & Stats
AU$2.06
-AU$0.15(-5.07%)
At close: 4:00 PM EST
AU$2.06
-AU$0.15(-5.07%)
Day’s Range― - ―
52-Week RangeAU$1.52 - AU$3.31
Previous CloseN/A
Volume5.54M
Average Volume (3M)4.33M
Market Cap
AU$2.64B
Enterprise ValueAU$1.96B
Total Cash (Recent Filing)AU$161.16M
Total Debt (Recent Filing)AU$128.16M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,290,302,200
10 Day Avg. Volume4,518,407
30 Day Avg. Volume4,325,729
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.83Price Target Upside85.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$127.60M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained, large percentage revenue growth driven by product sales indicates accelerating commercial adoption. Over a 2–6 month horizon this strengthens the company's ability to invest in launch infrastructure, fund follow-on trials and absorb fixed costs, improving long-term commercial durability.
Successful Commercial Launch And Payer CoverageEarly center penetration plus broad insurance and Medicaid coverage creates durable market access and reimbursement advantages. This reduces adoption friction, supports predictable hospital uptake, and raises the bar for competitors while enabling scale in pediatric acute GvHD over coming quarters.
Strong Cash Position And High Gross MarginA sizable cash balance combined with very high gross margins provides a durable buffer to fund commercialization and further trials without immediate dilution. High product-level margins imply scalable unit economics once fixed commercial costs are absorbed over the medium term.
Bears Say
Persistent Unprofitability And Negative ROENegative ROE and ongoing net losses reflect structural profitability challenges. Over 2–6 months this constrains shareholder returns, increases reliance on external capital if cash burn persists, and limits the company's ability to convert revenue growth into sustainable net earnings.
Operating Cash Flow Weakness Despite FCF GrowthNegative operating cash flow signals underlying cash generation issues from core operations despite one-time or timing-related free cash flow gains. This structural mismatch can necessitate financing or cutbacks if product sales volatility persists, elevating execution risk over the medium term.
Rising Operating Expenses From Commercial BuildMaterial increases in selling and admin costs reflect a higher fixed-cost base from commercialization. If revenue growth slows, elevated SG&A will pressure margins and cash flow. Maintaining profitable scale requires sustained uptake; otherwise expense leverage can materially weaken financial durability.
Mesoblast Limited News
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$1.51 and its highest was AU$3.31 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$2.64B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 161 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.034.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,290,302,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.044 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.83 (85.91% Upside)
AU$3.83 (85.91% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 97%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $15.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-18.31%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MSB Company Deck
MSB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive trajectory for Mesoblast, driven by the successful commercial launch of Ryoncil and significant revenue growth. Despite increased expenses and some regulatory challenges, the company shows robust market potential and financial health.View all AU:MSB earnings summariesMSB Stock 12 Month Forecast
Average Price Target
AU$3.83
▲(85.91% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Neuren Pharmaceuticals Limited
―
Orthocell Ltd
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---